Hepatic Resection Compared to Chemoembolization in Intermediate- to Advanced-Stage Hepatocellular Carcinoma: A Comment For Moving Forward

被引：7
|
作者：
Mo, Dun-Chang [1 ]
Jia, Rong-Rong [2 ]
Zhong, Jian-Hong [2 ]
机构：
[1] Guangxi Med Univ, Affiliated Hosp 3, Radiotherapy Dept, Nanning, Peoples R China
[2] Guangxi Med Univ, Affiliated Tumor Hosp, Hepatobiliary Surg Dept, Nanning, Peoples R China
来源：
HEPATOLOGY | 2019年 / 70卷 / 01期
关键词：
D O I：
10.1002/hep.30409
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：446 / 447
页数：2
相关论文
共 50 条
  • [21] Efficacy Of Apatinib In Transcatheter Arterial Chemoembolization (TACE) Refractory Intermediate And Advanced-Stage Hepatocellular carcinoma: A Propensity Score Matching Analysis
    Qiu, Zhiyu
    Shen, Lujun
    Chen, Shuanggang
    Qi, Han
    Cao, Fei
    Xie, Lin
    Fan, Weijun
    [J]. CANCER MANAGEMENT AND RESEARCH, 2019, 11 : 9321 - 9330
  • [22] Transarterial chemoembolization versus resection for intermediate-stage (BCLC B) hepatocellular carcinoma
    Kim, Jun Young
    Sinn, Dong Hyun
    Gwak, Geum-Youn
    Choi, Gyu-Seong
    Saleh, Aldosri Meshal
    Joh, Jae-Won
    Cho, Sung Ki
    Shin, Sung Wook
    Carriere, Keumhee Chough
    Ahn, Joong Hyun
    Paik, Yong-Han
    Choi, Moon Seok
    Lee, Joon Hyeok
    Koh, Kwang Cheol
    Paik, Seung Woon
    [J]. CLINICAL AND MOLECULAR HEPATOLOGY, 2016, 22 (02) : 250 - 258
  • [23] Liver resection versus transarterial chemoembolization for the treatment of intermediate-stage hepatocellular carcinoma
    Chen, Shuling
    Jin, Huilin
    Dai, Zihao
    Wei, Mengchao
    Xiao, Han
    Su, Tianhong
    Li, Bin
    Liu, Xin
    Wang, Yu
    Li, Jiaping
    Shen, Shunli
    Zhou, Qi
    Peng, Baogang
    Peng, Zhenwei
    Peng, Sui
    [J]. CANCER MEDICINE, 2019, 8 (04): : 1530 - 1539
  • [24] LIVER RESECTION VERSUS TRANSARTERIAL CHEMOEMBOLIZATION FOR THE TREATMENT OF INTERMEDIATE-STAGE HEPATOCELLULAR CARCINOMA
    Zhu, Wanjie
    Chen, Shuling
    Jin, Huilin
    [J]. GUT, 2019, 68 : A128 - A128
  • [25] Predicting early hepatocellular carcinoma recurrence after resection: A comment for moving forward
    Zhang, Xiao-Ying
    Ou, Jie
    Chen, Jia-Yi
    Li, Wen-Wu
    [J]. JOURNAL OF HEPATOLOGY, 2019, 70 (03) : 567 - 568
  • [26] Additive Benefit of Transarterial Chemoembolization and Sorafenib in Treating Advanced-Stage Hepatocellular Carcinoma: Propensity analysis
    Choi, Gwang Hyeon
    Shim, Ju Hyun
    Lee, Danbi
    Kim, Kang Mo
    Lim, Young-Suk
    Lee, Han Chu
    Chung, Young-Hwa
    Lee, Yung Sang
    Suh, Dong Jin
    Kang, Yoon-Koo
    [J]. HEPATOLOGY, 2012, 56 : 469A - 469A
  • [27] Comment on: Surgical Resection Versus Transarterial Chemoembolization for BCLC Stage C Hepatocellular Carcinoma
    Wang, Yan-Yan
    Zhong, Jian-Hong
    Qin, Hong-Gui
    Li, Le-Qun
    [J]. JOURNAL OF SURGICAL ONCOLOGY, 2015, 112 (08) : 907 - 908
  • [28] Clinical features and prognostic analysis of transarterial chemoembolization combined with targeted immunotherapy in the treatment of patients with hepatitis B virus-related intermediate- and advanced-stage hepatocellular carcinoma with secondary cholestas
    王柠柠
    [J]. China Medical Abstracts (Internal Medicine), 2024, 41 (01) : 51 - 52
  • [29] Sorafenib versus Transarterial chemoembolization for advanced-stage hepatocellular carcinoma: a cost-effectiveness analysis
    Shuling Chen
    Zhenwei Peng
    Mengchao Wei
    Weifeng Liu
    Zihao Dai
    Haibo Wang
    Jie Mei
    Mingfong Cheong
    Hanmei Zhang
    Ming Kuang
    [J]. BMC Cancer, 18
  • [30] Sorafenib versus Transarterial chemoembolization for advanced-stage hepatocellular carcinoma: a cost-effectiveness analysis
    Chen, Shuling
    Peng, Zhenwei
    Wei, Mengchao
    Liu, Weifeng
    Dai, Zihao
    Wang, Haibo
    Mei, Jie
    Cheong, Mingfong
    Zhang, Hanmei
    Kuang, Ming
    [J]. BMC CANCER, 2018, 18
12345